Reckitt Benckiser to pay $1.4bn to end opioid addiction treatment probes
UK drugmaker to increase provision to $1.5bn to cover the cost of the investigations in former business Indivior
11 July 2019 - 17:23
Reckitt Benckiser has agreed to pay up to $1.4bn to end US federal investigations into the marketing of an opioid addiction treatment by its former business Indivior, lifting a cloud that has been hanging over the British company for years.
While the settlement is significantly higher than the $400m that the consumer goods group had set aside to cover the cost of the investigations, analysts said it could allow the company’s new CEO to focus on a turnaround plan...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.